The Pulse
OpenAI Lists a Second Rosalind Model at the Same API Rates
OpenAI’s API pricing page now lists gpt-rosalind-discovery alongside gpt-rosalind-research at identical per-token rates. The listing does not describe the second model’s capabilities or say when it will be available.
AI.info Team · Written with AI ·
“This is the first release in our GPT‑Rosalind life sciences model series, and we will continue to expand the frontiers of the model’s biochemical reasoning capabilities across long-horizon, tool-heavy scientific workflows.”
OpenAI, introducing GPT-Rosalind
Two model names share one price
OpenAI’s API pricing page lists a second entry in its Rosalind life-sciences group: gpt-rosalind-discovery. It appears beside gpt-rosalind-research, with both priced at $5 per million input tokens, $0.50 per million cached input tokens and $25 per million output tokens.
The rate card calls the pair “Our latest Rosalind models,” but provides no separate description of Discovery. It does not say what tasks the model handles, how it differs from Research, or when customers can use it. The listing establishes that OpenAI has added the identifier and prices; it does not establish that the two models have the same capabilities or access terms.
OpenAI’s earlier release described a series
OpenAI introduced GPT-Rosalind on April 16, 2026, describing it as a model for research across biology, drug discovery and translational medicine. The company said it was the first release in a life-sciences model series, with work aimed at biochemical reasoning and long, tool-heavy research workflows.
In an update dated September 11, OpenAI said GPT-Rosalind was leaving research preview and becoming available globally to eligible organizations through a trusted-access program. The company said pricing would take effect October 5. Its earlier announcement also described use in ChatGPT, Codex and the API for qualified customers, and introduced a Codex research plugin connecting to more than 50 scientific tools and data sources.
The billing note names Research, not Discovery
The pricing page’s billing note says charges for gpt-rosalind-research begin October 5, 2026. It also says cache-write pricing does not apply to “this model” and limits access to approved internal research through the trusted-access program. The note names Research specifically; the page does not separately spell out Discovery’s launch date or access conditions.
OpenAI’s Help Center describes GPT-Rosalind access as limited to approved organizations and says API use is for internal research tools, workflows and applications, not customer-facing products or external commercial applications. That guidance concerns GPT-Rosalind generally and does not explain whether the newly listed Discovery entry has a separate rollout or eligibility policy.
A second SKU, without a second description
The naming suggests a distinction between research and discovery, but OpenAI’s public listing does not define one. The company’s announcement and Help Center material describe GPT-Rosalind as a life-sciences research model; neither explains Discovery as a separate product or identifies a capability gap it is meant to fill.
For now, the concrete change is on the rate card: two Rosalind model identifiers, each carrying the same three token prices. The page ties its dated billing and access note to Research, while leaving the Discovery row without a product description or an availability date.